These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 16678029

  • 21. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ.
    Clin Transplant; 2005 Feb; 19(1):130-6. PubMed ID: 15659146
    [Abstract] [Full Text] [Related]

  • 22. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Feb; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 23. Sirolimus experience in heart transplantation.
    Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A.
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [Abstract] [Full Text] [Related]

  • 24. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
    Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, Ruano J, Ruisanchez C, Martin-Duran R.
    Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
    [Abstract] [Full Text] [Related]

  • 25. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 26. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
    Arora-Gupta N, Davies P, McKiernan P, Kelly DA.
    Pediatr Transplant; 2004 Apr 27; 8(2):145-50. PubMed ID: 15049794
    [Abstract] [Full Text] [Related]

  • 27. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.
    Clin Transplant; 2009 Apr 27; 23(3):351-60. PubMed ID: 19208105
    [Abstract] [Full Text] [Related]

  • 28. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO.
    Transplant Proc; 2009 Apr 27; 41(6):2659-63. PubMed ID: 19715995
    [Abstract] [Full Text] [Related]

  • 29. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 30. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F, de Prada JA, Exposito V, García-Camarero T, Fernández-Friera L, Llano M, Ruano J, Martín-Durán R.
    J Heart Lung Transplant; 2008 Oct 27; 27(10):1135-41. PubMed ID: 18926406
    [Abstract] [Full Text] [Related]

  • 31. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 32. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.
    Chinnock TJ, Shankel T, Deming D, Cutler D, Sahney S, Fitts J, Chinnock RE.
    Pediatr Transplant; 2011 Nov 27; 15(7):746-9. PubMed ID: 21883751
    [Abstract] [Full Text] [Related]

  • 33. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S, Kielstein JT, Kayser D, Bröcker V, Becker JU, Hiss M, Schiffer M, Sommerwerck U, Haller H, Strüber M, Welte T, Gottlieb J.
    Nephrol Dial Transplant; 2011 Sep 27; 26(9):3032-8. PubMed ID: 21310739
    [Abstract] [Full Text] [Related]

  • 34. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
    Bajjoka I, Hsaiky L, Brown K, Abouljoud M.
    Liver Transpl; 2008 Jan 27; 14(1):66-72. PubMed ID: 18161842
    [Abstract] [Full Text] [Related]

  • 35. Recovery of chronic renal impairment with sirolimus after lung transplantation.
    Venuta F, De Giacomo T, Rendina EA, Quattrucci S, Mercadante E, Cimino G, Ibrahim M, Diso D, Bachetoni A, Coloni GF.
    Ann Thorac Surg; 2004 Dec 27; 78(6):1940-3. PubMed ID: 15561004
    [Abstract] [Full Text] [Related]

  • 36. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov 27; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 37. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V, Abraham G, Fathima N, Sundaram V, Reddy YN, Mathew M, Sathiah V.
    Saudi J Kidney Dis Transpl; 2010 Jan 27; 21(1):37-42. PubMed ID: 20061690
    [Abstract] [Full Text] [Related]

  • 38. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
    Forgacs B, Merhav HJ, Lappin J, Mieles L.
    Transplant Proc; 2005 May 27; 37(4):1912-4. PubMed ID: 15919502
    [Abstract] [Full Text] [Related]

  • 39. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 40. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.